Pfizer's COVID-19 vaccine "Cominatiju 0.1mg/mL," which is subject to vaccination for children and adolescents aged 5 to 11, has obtained an item license.

The MFDS (Minister Kim Kang-rip) announced on the 23rd that Pfizer Pharmaceutical Korea has approved "Comirati 0.1mg/mL" applied for permission as an imported item.

Depending on the design of the clinical trial, different doses were allocated at the age of 11 and 12, and in the case of 5 to 11 years old, the dose was selected in consideration of the results of the immune response obtained from the clinical trial (phase 1).

The vaccine is an mRNA vaccine jointly developed by Pfizera of the U.S. and Bioentech of Germany and imp